Harmony Biosciences Holdings, Inc. $HRMY Stock Holdings Increased by Hsbc Holdings PLC

Hsbc Holdings PLC raised its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 59.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,589 shares of the company’s stock after buying an additional 21,919 shares during the quarter. Hsbc Holdings PLC owned about 0.10% of Harmony Biosciences worth $2,193,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Rockefeller Capital Management L.P. lifted its stake in Harmony Biosciences by 30.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 17,783 shares of the company’s stock worth $665,000 after purchasing an additional 4,148 shares during the last quarter. Invesco Ltd. raised its stake in Harmony Biosciences by 11.8% during the fourth quarter. Invesco Ltd. now owns 450,805 shares of the company’s stock worth $16,869,000 after acquiring an additional 47,517 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in Harmony Biosciences in the fourth quarter worth about $525,000. State of Tennessee Department of Treasury boosted its stake in Harmony Biosciences by 37.0% in the fourth quarter. State of Tennessee Department of Treasury now owns 36,150 shares of the company’s stock valued at $1,320,000 after acquiring an additional 9,768 shares during the period. Finally, Mackenzie Financial Corp acquired a new position in Harmony Biosciences in the fourth quarter valued at approximately $1,529,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY traded down $1.37 during midday trading on Friday, hitting $36.84. 668,823 shares of the company’s stock were exchanged, compared to its average volume of 720,483. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.58 and a quick ratio of 3.56. The stock’s 50 day moving average price is $33.19 and its 200-day moving average price is $32.84. The firm has a market cap of $2.13 billion, a P/E ratio of 14.85, a PEG ratio of 0.35 and a beta of 0.94. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). The business had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.78 earnings per share. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.26 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Zacks Research upgraded Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft upped their price objective on Harmony Biosciences from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Tuesday, June 30th. Weiss Ratings raised Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. Truist Financial raised their target price on Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research note on Friday, May 8th. Finally, HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a report on Wednesday, June 24th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $42.50.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.